Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
Phase 2
55
about 5.5 years
18+
2 sites in PA
What this study is about
Researchers are testing if a chemotherapy combination called gemcitabine and carboplatin (GC) works to treat advanced urothelial cancer in people who have already been treated with enfortumab vedotin and pembrolizumab (EVP). The trial will also learn about the efficacy and safety of GC in these patients. Researchers will trial how GC affects survival, cancer control, and quality of life.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Carboplatin
- 2.Take Gemcitabine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
carboplatin, gemcitabine
injection (Injection)
Primary: Best overall response (Complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) to gemcitabine plus carboplatin defined per RECIST v 1.1
Secondary: To evaluate overall survival (OS) as a function of time since study enrollment in patients receiving GC after prior exposure to EVP, To evaluate progression free survival (PFS) as a function of time since study enrollment in patients receiving GC after prior exposure to EVP, To evaluate the disease control rate (DCR) of gemcitabine plus carboplatin after prior exposure to EVP